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San Antonio Breast Cancer Symposium Abstract 
Ongoing Clinical Trial 
 
PRIMROSE: A BCTRCG prospective study of treatment and outcomes related to CNS 
disease secondary to breast cancer in the UK 
VWT Cheng1, HS McKenzie2, A Kwan3, A Konstantis4, R Ma5, PJ Teo6, A Fitzpatrick7, S Mehta8, 
A Mukhopadhyay9 & C Palmieri10 on behalf of the PRIMROSE study group 
1Leeds Cancer Centre, Leeds, 2University of Southampton, Southampton, 3University of Sheffield, 
Sheffield, 4The Princess Alexandra NHS Trust, Harlow 5Oxford University Hospitals NHS Trust, Oxford, 
6Worcestershire Acute Hospitals NHS Trust, Worcester, 7Institute of Cancer Research, London, 
8Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, 9University of Glasgow, Glasgow, 
10University of Liverpool, Liverpool 
 
Introduction 
Breast cancer brain metastasis (BCBM) is a particular feature of HER2-positive and triple 
negative breast cancer (BC) and is becoming more common. This reflects the improved 
survival of patients living with metastatic breast cancer as well as increased cross-sectional 
imaging of the central nervous system with magnetic resonance imaging (1). The 
development of BCBM on the background of adequately controlled extracranial disease is an 
increasingly prevalent clinical scenario. BCBM causes significant morbidity and mortality; 
unfortunately the efficacy of systemic treatment is extremely limited and, at present, no 
systemic therapies are specifically approved for the treatment of BCBM (2). Basic and 
translational research to understand the pathophysiology of BCBM remains limited by a lack 
of access to annotated clinical material. Such research is needed if preventative and novel 
treatment strategies are to be developed. Moreover, there is currently a lack of basic 
contemporaneous information regarding the incidence and management of BCBM in the UK, 
how it may vary across the country and its impact on patient outcomes. Finally, clinical studies 
have been hampered by a lack of a central resource to aid feasibility work and to identify 
potentially eligible patients.   
 
Study design 
PRIMROSE will use the trainee collaborative model to establish an observational prospective 
UK cohort of newly diagnosed BCBM. Data collected will include routine clinico-pathological 
information, prior adjuvant and metastatic treatment as well as BCBM-related information 
including presentation, management and outcome. Anonymised data will be collated in a 
secure central REDCap database. All hospitals in the UK will be eligible to register patients 
driven by trainees from all specialties via the UK Breast Cancer Trainees Research 
Collaborative Group (BCTRCG) network.  
 
Eligibility criteria 
Inclusion criteria: male or female patients aged >16 years of age with histologically and/or 
cytologically confirmed BC with involvement of the brain parenchyma. There are no formal 
exclusion criteria. Patients with leptomeningeal disease will be registered with data being 
collected in a separate project (PRIMROSE-LMD). 
 
Aims 
The overarching objectives include defining the prevalence, management and outcome of 
BCBM in the UK. 
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Endpoints  
*Primary Endpoint: Overall survival from initial diagnosis of CNS involvement. Secondary 
Endpoints will include: 1. Time to initial CNS involvement from initial diagnosis of MBC; 2. 
Therapeutic interventions for management of CNS disease; 3. Time to intracranial tumour 
progression (for each line of therapy given for CNS disease); 4. Overall survival from MBC 
diagnosis; 5. Cause of death: progressive CNS disease versus progressive disease at other sites. 
*Information will be presented for the whole cohort as well as by breast cancer subtype 
 
Patient accrual 
Patient accrual is due to commence in July 2019 and continue will for 2 years in the first 
instance. There is no predefined target accrual. 
 
Contact information 
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